Publications by authors named "Jim Slattery"

Claim this Profile
O
Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice.
Jim Slattery, Chantal Quinten, Gianmario Candore, Luis Pinheiro, Robert Flynn

Br J Clin Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Mandatory Reporting of Non-Serious Safety Reports to EudraVigilance on the Detection of Adverse Reactions.
Gianmario Candore, Sebastian Monzon, Jim Slattery, Loris Piccolo, Rodrigo Postigo

Drug Saf· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is There an Increased Risk of Hepatotoxicity with Metamizole? A Comparative Cohort Study in Incident Users.
Karin Hedenmalm, Alexandra Pacurariu, Jim Slattery, Xavier Kurz, Gianmario Candore

Drug Saf· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What are the patients' and health care professionals' understanding and behaviors towards adverse drug reaction reporting and additional monitoring?
Justina Januskiene, Andrej Segec, Jim Slattery, Georgy Genov, Kelly Plueschke

Pharmacoepidemiol Drug Saf· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data.
Andrej Segec, Jim Slattery, Daniel R Morales, Justina Januskiene, Xavier Kurz

Pharmacoepidemiol Drug Saf· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?
Jim Slattery, Xavier Kurz

Pharmacoepidemiol Drug Saf· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different Strategies to Execute Multi-Database Studies for Medicines Surveillance in Real-World Setting: A Reflection on the European Model.
Rona Gini, Miriam C J Sturkenboom, Janet Sultana, Alison Cave, Annalisa Landi, Jim Slattery

Clin Pharmacol Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of population-based nested case-control studies.
Daniel R Morales, Alexandra Pacurariu, Jim Slattery, Xavier Kurz

Br J Clin Pharmacol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can We Rely on Results From IQVIA Medical Research Data UK Converted to the Observational Medical Outcome Partnership Common Data Model?: A Validation Study Based on Prescribing Codeine in Children.
Gianmario Candore, Karin Hedenmalm, Jim Slattery, Alison Cave, Xavier Kurz

Clin Pharmacol Ther· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy.
Daniel Morales, Alexandra Pacurariu, Jim Slattery, Luis Pinheiro, Patricia McGettigan

JAMA Neurol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescribing patterns of tramadol in adults in IMS® primary care databases in France and Germany between 1 January 2006 and 30 June 2016.
Karin Hedenmalm, Jim Slattery, Izabela Skibicka-Stepien, Xavier Kurz, Daniel Morales

Eur J Clin Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study.
Daniel R Morales, Jim Slattery, Alexandra Pacurariu, Luis Pinheiro, Patricia McGettigan

Clin Drug Investig· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study.
Daniel R Morales, Jim Slattery, Alexandra Pacurariu, Luis Pinheiro, Patricia McGettigan

Clin Drug Investig· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cohort Study of Psychiatric Adverse Events Following Exposure to Levonorgestrel-Containing Intrauterine Devices in UK General Practice.
Jim Slattery, Daniel Morales, Luis Pinheiro, Xavier Kurz

Drug Saf· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK: Descriptive Population-Based Study.
Daniel R Morales, Jim Slattery, Luis Pinheiro, Xavier Kurz, Karin Hedenmalm

Clin Drug Investig· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation.
Alexandra Pacurariu, Kelly Plueschke, Patricia McGettigan, Daniel R Morales, Jim Slattery

BMJ Open· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection.
Rodrigo Postigo, Sabine Brosch, Jim Slattery, Anja van Haren, Jean-Michel Dogné

Drug Saf· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is patient exposure preapproval and postapproval a determinant of the timing and frequency of occurrence of safety issues?
Alexandra C Pacurariu, Christina E Hoeve, Peter Arlett, Georgy Genov, Jim Slattery

Pharmacoepidemiol Drug Saf· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance.
Luis C Pinheiro, Gianmario Candore, Cosimo Zaccaria, Jim Slattery, Peter Arlett

Pharmacoepidemiol Drug Saf· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations.
Daniel R Morales, Jim Slattery, Stephen Evans, Xavier Kurz

BMC Med· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Jacoline C Bouvy, Kevin Blake, Jim Slattery, Marie L De Bruin, Peter Arlett

Pharmacoepidemiol Drug Saf· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Reporting in the EU: Analysis of EudraVigilance Data.
Marin Banovac, Gianmario Candore, Jim Slattery, Francois Houÿez, David Haerry

Drug Saf· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Good Signal Detection Practices: Evidence from IMI PROTECT.
Antoni F Z Wisniewski, Andrew Bate, Cedric Bousquet, Andreas Brueckner, Gianmario Candore, Jim Slattery

Drug Saf· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures.
Patrick C Souverein, Victoria Abbing-Karahagopian, Elisa Martin, Consuelo Huerta, Francisco de Abajo, Jim Slattery

Pharmacoepidemiol Drug Saf· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case-only designs for studying the association of antidepressants and hip or femur fracture.
Mark C H de Groot, Gianmario Candore, Md Jamal Uddin, Patrick C Souverein, M Sanni Ali, Jim Slattery

Pharmacoepidemiol Drug Saf· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis